Cara Therapeutics Inc CARA:NASDAQ

RT Quote | NASDAQ | USD
Last | 05/23/22 EDT
8.55quote price arrow down-0.13 (-1.50%)
Volume
505,374
52 week range
7.40 - 18.93
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close8.55
  • 52 Week High18.93
  • 52 Week High Date11/09/21
  • 52 Week Low7.40
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap458.19M
  • Shares Out53.59M
  • 10 Day Average Volume1.10M
  • Dividend-
  • Dividend Yield-
  • Beta1.18
  • YTD % Change-29.8

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close8.55
  • 52 Week High18.93
  • 52 Week High Date11/09/21
  • 52 Week Low7.40
  • 52 Week Low Date05/09/22
  • Market Cap458.19M
  • Shares Out53.59M
  • 10 Day Average Volume1.10M
  • Dividend-
  • Dividend Yield-
  • Beta1.18
  • YTD % Change-29.8

RATIOS/PROFITABILITY

  • EPS (TTM)-1.79
  • P/E (TTM)-4.79
  • Fwd P/E (NTM)-5.61
  • EBITDA (TTM)-93.184M
  • ROE (TTM)-42.75%
  • Revenue (TTM)25.88M
  • Gross Margin (TTM)10.47%
  • Net Margin (TTM)-358.88%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/08/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cara Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical...
Christopher Posner
President, Chief Executive Officer, Director
Thomas Reilly
Chief Financial Officer
Address
4 Stamford Plz
Stamford, CT
06902-3834
United States

Top Peers

SYMBOLLASTCHG%CHG
ATRA
Atara Biotherapeutics Inc
4.98-0.18-3.49%
NRIX
Nurix Therapeutics Inc
10.11+0.13+1.30%
IMTX
Immatics NV
7.20+0.14+1.98%
MESO
Mesoblast Ltd
3.53+0.02+0.57%
IDYA
IDEAYA Biosciences Inc
10.74-0.26-2.36%